TP-064 / Takeda - LARVOL DELTA

[VIRTUAL] TP064 TOBACCO PRODUCT EXPOSURES AND RESPIRATORY HEALTH (ATS 2021) - No abstract available

Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy. (PubMed, J Exp Med) - "Moreover, mouse genetic and single-cell analyses demonstrated that the homozygous deletion of Arid1a confers a competitive disadvantage through the activation of the p53 pathway, highlighting its distinct dosage-dependent roles. Using this unique vulnerability of Arid1a mutated GC cells, our combined treatment with the epigenetic inhibitor, TP064, and the p53 agonist, Nutlin-3, inhibited growth of Arid1a heterozygous tumor organoids, providing a novel therapeutic option for GC."

Journal • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • ARID1A